Leerink Partners Starts Coverage on Nautilus Biotechnology Amid Options Activity
What happened
Leerink Partners started coverage of Nautilus Biotechnology on October 6, 2026. On that day, the company received unusual options trading activity, with traders acquiring 3,253 call options, an increase of approximately 1,427% compared to the average daily volume of 213 call options. During the second quarter, several institutional investors also increased their holdings in Nautilus Biotechnology.
From dailypolitical.com
Why it matters
The activity indicates significant interest from institutional investors and traders in Nautilus Biotechnology. Several firms, including Susquehanna International Group LLP, Corient Private Wealth LP, and TD Waterhouse Canada Inc., boosted their positions in the company during the second quarter.
From dailypolitical.com
Who's involved
- Leerink partnersU.S. investment bank that started coverage on Nautilus Biotechnology
Keep exploring
The entities involved
-
Leerink partners
U.S. investment bank
Related events
- Leerink Partners began coverage on Novogen Limited shares on October 20, 2026.
- Leerink Partners cut its shares rating for Akebia Therapeutics on November 3, 2026.
- Leerink Partners reduced its target price for Keros Therapeutics on November 2, 2026.
- Leerink partners and Jefferies Financial Group issued ratings for Latigo Biotherapeutics, which also appointed Todd Smith as CEO.
- Jefferies, Citigroup, and Leerink Partners issued rating updates and price targets for Phathom Pharmaceuticals.